Bayer Pharmaceuticals: Executive Summary

Overview

• Bayer Pharmaceuticals focus on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics focused on the areas of oncology, hematology, ophthalmology and, in the medium term, cell and gene therapy, and radiology business.         
  The prescription products of Bayer Pharmaceuticals are primarily distributed through wholesalers, pharmacies and hospitals

Business Segments

• Bayer Pharmaceuticals consists of products under ophthalmology, radiology and women’s healthcare segments
  Bayer Pharmaceuticals high performing products includes Eylea in ophthalmology, Nubeqa in cancer, Kerendia in  chronic kidney disease and type 2 diabetes

Financial Overview

• Bayer Pharmaceuticals' full year 2021 revenues was $19.4 Bn which grew from $17.2 Bn from 2020, reflecting balanced, broad-based revenue growth across the businesses 
  Bayer Pharmaceuticals has projected major revenue boost in 2021 on back of continued increase in sales of major pharmaceuticals product
  Biggest driver of growth in 2021 has been Xarelto, earning Bayer Pharmaceuticals $5 billion in revenue compared to $4.8 billion in 2020

Acquisition

• Bayer completed acquisition of 100% of the shares in biotech company KaNDy Therapeutics Ltd., at around US$ 387 million, expanding its development portfolio in women’s health. KaNDy Therapeutics is developing Treatment for the treatment of menopause.
  Bayer acquired 100% of the shares in Asklepios BioPharmaceutical, Inc. which specializes in the research, development and manufacturing of gene therapies across different therapeutic areas.